Ipsen mourns the passing of Henri Beaufour, a founding family Board member

Core Viewpoint - The passing of Henri Beaufour, a significant figure in Ipsen's history, is a profound loss for the company and its stakeholders, highlighting his contributions to the company's strategic direction and values established by the founding family [1][2][4]. Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in three therapeutic areas: Oncology, Rare Disease, and Neuroscience, with nearly 100 years of development experience [6]. - The company operates in over 40 countries and partners globally to deliver medicines to patients in more than 100 countries [6]. Leadership and Governance - Henri Beaufour was a long-serving member of the Board of Directors and a major shareholder, recognized for his dedication and contributions to Ipsen's growth [4]. - The Board of Directors and Executive Leadership Team expressed their condolences to the Beaufour family and reaffirmed their commitment to continue pursuing the company's strategic priorities [2][5]. Shareholder Intent - Beech Tree and Highrock, as controlling shareholders, reiterated their intent to act in the best interests of the Ipsen group and support its ongoing development [3].